Featured Research

from universities, journals, and other organizations

New rheumatoid arthritis criteria to stave off disabling disease for thousands of people

Date:
August 12, 2010
Source:
BMJ-British Medical Journal
Summary:
New criteria for rheumatoid arthritis (RA) could prevent thousands of people from developing disabling late stage disease, by redefining how RA should be classified.

New criteria for rheumatoid arthritis (RA), published in the Annals of Rheumatic Diseases, could prevent thousands of people from developing disabling late stage disease, by redefining how RA should be classified.

Rheumatoid arthritis is a progressive autoimmune inflammatory disease, primarily of the joints. If untreated, it leads to damage of bone and cartilage, joint deformities and disability. Around 350,000 people in the UK are living with RA, which affects around three times as many women as men.

Late stage rheumatoid arthritis has also been linked to a higher risk of serious heart disease and premature death.

The new criteria, which were developed jointly in three phases by the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR), are based on data from real patients and clinical consensus.

They replace existing ACR criteria published in 1987, which focused on established, rather than early indicators of disease. The new 2010 criteria focus on early diagnosis and treatment, which has become increasingly important with the advent of more effective drug treatments over the past decade.

If picked up early, synthetic and biological disease modifying antirheumatic drugs (DMARDs) can prevent the destructive and disabling joint damage, which is a hallmark of late stage RA.

The new criteria aim to recognise RA early on in its development, in a bid to target preventive treatment more effectively and channel into clinical trials patients who could benefit from promising new therapies for the disease.

The new criteria classify "definite RA" as:

  • The confirmed presence of synovitis -- inflammation of the synovial membrane that lines the joint -- in at least one joint
  • The absence of an alternative diagnosis to explain the synovitis, for example gout or arthritis triggered by infection (reactive arthritis)
  • A combined score of 6 or more from each of the following four domains:
    • number and sites of affected joints
    • blood tests results (for autoantibodies indicative of RA)
    • evidence of an increase in inflammatory proteins (known as the acute phase response)
    • how long symptoms have lasted

"The new criteria redefine RA, reflecting our collective hope that in the future, RA will no longer be characterised by erosive joint disease and persistence of symptoms, although these characteristics will continue to define established or longstanding untreated disease," write the working party authors.

The importance of treating RA promptly has been recognised both by NICE (management guidelines for treatment of RA) and the national Audit Office (management of RA).


Story Source:

The above story is based on materials provided by BMJ-British Medical Journal. Note: Materials may be edited for content and length.


Cite This Page:

BMJ-British Medical Journal. "New rheumatoid arthritis criteria to stave off disabling disease for thousands of people." ScienceDaily. ScienceDaily, 12 August 2010. <www.sciencedaily.com/releases/2010/08/100812192101.htm>.
BMJ-British Medical Journal. (2010, August 12). New rheumatoid arthritis criteria to stave off disabling disease for thousands of people. ScienceDaily. Retrieved August 21, 2014 from www.sciencedaily.com/releases/2010/08/100812192101.htm
BMJ-British Medical Journal. "New rheumatoid arthritis criteria to stave off disabling disease for thousands of people." ScienceDaily. www.sciencedaily.com/releases/2010/08/100812192101.htm (accessed August 21, 2014).

Share This




More Health & Medicine News

Thursday, August 21, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Drug Used To Treat 'Ebola's Cousin' Shows Promise

Drug Used To Treat 'Ebola's Cousin' Shows Promise

Newsy (Aug. 21, 2014) An experimental drug used to treat Marburg virus in rhesus monkeys could give new insight into a similar treatment for Ebola. Video provided by Newsy
Powered by NewsLook.com
Cadavers, a Teen, and a Medical School Dream

Cadavers, a Teen, and a Medical School Dream

AP (Aug. 21, 2014) Contains graphic content. He's only 17. But Johntrell Bowles has wanted to be a doctor from a young age, despite the odds against him. He was recently the youngest participant in a cadaver program at the Indiana University NW medical school. (Aug. 21) Video provided by AP
Powered by NewsLook.com
American Ebola Patients Released: What Cured Them?

American Ebola Patients Released: What Cured Them?

Newsy (Aug. 21, 2014) It's unclear whether the American Ebola patients' recoveries can be attributed to an experimental drug or early detection and good medical care. Video provided by Newsy
Powered by NewsLook.com
Lost Brain Cells To Blame For Sleep Problems Among Seniors

Lost Brain Cells To Blame For Sleep Problems Among Seniors

Newsy (Aug. 21, 2014) According to a new study, elderly people might have trouble sleeping because of the loss of a certain group of neurons in the brain. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins